# US 2008/0188457 A1 · Modulation of Neurogenesis with Biguanides and GSK3-beta Agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188457 A1
- Document ID: US20080188457A1
- Status: Published application
- Kind: A1
- Application number: 12/024,923
- Filed: 2008-02-01
- Published: 2008-08-07
- Earliest claimed: 2007-02-02
- Assignees: BrainCells, Inc.
- Inventors: Carrolee Barlow; Todd Carter; Andrew Morse; Kai Treuner; Kym I. Lorrain
- Web page: https://patentgrep.com/patent/US20080188457A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/4355: the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/32: Alcohol-abuse
- A61P 25/36: Opioid-abuse
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of one or more biguanides in combination with one or more GSK3-β agents, to stimulate or activate the formation of new nerve cells.

## Claims

### Claim 1

A composition comprising one or more biguanides in combination with one or more GSK3-β agents.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the one or more biguanides is metformin, phenformin, buformin, or proguanil; and wherein the one or more GSK3-β agents is a paullone.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the one or more biguanides is metformin; and wherein the paullone is alsterpaullone, azakenpaullone, gwennpaullone, or kenpaullone.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the paullone is azakenpaullone.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the composition is in a pharmaceutically acceptable formulation.

### Claim 6 (depends on 1)

A method of stimulating or increasing neurogenesis in a cell or tissue, the method comprising contacting the cell or tissue with the compositon of claim 1, wherein the composition is effective to produce neurogenesis in the cell or tissue.

### Claim 7 (depends on 6)

The method of claim 6, wherein the cell or tissue is in an animal subject or a human patient.

### Claim 8 (depends on 7)

The method of claim 7, wherein the patient is in need of neurogenesis or has been diagnosed with a disease, condition, or injury of the central or peripheral nervous system.

### Claim 9 (depends on 6)

The method of claim 6, wherein the neurogenesis comprises differentiation of neural stem cells (NSCs) along a neuronal lineage.

### Claim 10 (depends on 6)

The method of claim 6, wherein the neurogenesis comprises differentiation of neural stem cells (NSCs) along a glial lineage.

### Claim 11 (depends on 6)

The method of claim 6, wherein the cell or tissue exhibits decreased neurogenesis or is subjected to an agent which decreases or inhibits neurogenesis.

### Claim 12 (depends on 7)

The method of claim 7, wherein the subject or patient has one or more chemical addiction or dependency.

### Claim 13 (depends on 6)

The method of claim 6, wherein the one or more biguanides is metformin, phenformin, buformin, or proguanil; and wherein the one or more GSK3-β agents is a paullone.

### Claim 14 (depends on 13)

The method of claim 13, wherein the one or more biguanides is metformin; and
wherein the paullone is alsterpaullone, azakenpaullone, gwennpaullone, or kenpaullone.

### Claim 15 (depends on 14)

The method of claim 14, wherein the paullone is azakenpaullone.

### Claim 16 (depends on 6)

The method of claim 6, wherein the composition is in a pharmaceutically acceptable formulation.

### Claim 17 (depends on 1)

A method of treating a nervous system disorder related to cellular degeneration, a psychiatric condition, cellular trauma and/or injury, or another neurologically related condition in a subject or patient, the method comprising administering the composition of claim 1, wherein the composition is effective to produce an improvement in the disorder in the subject or patient.

### Claim 18 (depends on 17)

The method of claim 17, wherein the nervous system disorder related to cellular degeneration is selected from a neurodegenerative disorder, a neural stem cell disorder, a neural progenitor cell disorder, a degenerative disease of the retina, an ischemic disorder, and combinations thereof.

### Claim 19 (depends on 17)

The method of claim 17, wherein the nervous system disorder related to a psychiatric condition is selected from a neuropsychiatric disorder, an affective disorder, depression, hypomania, panic attacks, anxiety, excessive elation, bipolar depression, bipolar disorder (manic-depression), seasonal mood (or affective) disorder, schizophrenia and other psychoses, lissencephaly syndrome, anxiety syndromes, anxiety disorders, phobias, stress and related syndromes, cognitive function disorders, aggression, drug and alcohol abuse, obsessive compulsive behavior syndromes, borderline personality disorder, non-senile dementia, post-pain depression, post-partum depression, cerebral palsy, post-traumatic stress disorder (PTSD), and combinations thereof.

### Claim 20 (depends on 17)

The method of claim 17, wherein the nervous system disorder related to cellular trauma and/or injury is selected from neurological traumas and injuries, surgery related trauma and/or injury, retinal injury and trauma, injury related to epilepsy, spinal cord injury, brain injury, brain surgery, trauma related brain injury, trauma related to spinal cord injury, brain injury related to cancer treatment, spinal cord injury related to cancer treatment, brain injury related to infection, brain injury related to inflammation, spinal cord injury related to infection, spinal cord injury related to inflammation, brain injury related to environmental toxin, spinal cord injury related to environmental toxin, and combinations thereof.

### Claim 21 (depends on 17)

The method of claim 17, wherein the neurologically related condition is selected from learning disorders, memory disorders, autism, attention deficit disorders, narcolepsy, sleep disorders, cognitive disorders, epilepsy, temporal lobe epilepsy, and combinations thereof.

### Claim 22 (depends on 17)

The method of claim 17, wherein the psychiatric condition comprises depression.

### Claim 23 (depends on 22)

The method of claim 22, wherein the depression is due to morphine, alcohol, or drug use by the subject or patient.

### Claim 24 (depends on 23)

The method of claim 23, wherein the nervous system disorder related to a psychiatric condition is an affective disorder.

### Claim 25 (depends on 24)

The method of claim 24, wherein the affective disorder is post-traumatic stress disorder (PTSD).

### Claim 26 (depends on 17)

The method of claim 17, wherein the one or more biguanides is metformin, phenformin, buformin, or proguanil; and wherein the one or more GSK3-β agents is a paullone.

### Claim 27 (depends on 26)

The method of claim 26, wherein the one or more biguanides is metformin; and
wherein the paullone is alsterpaullone, azakenpaullone, gwennpaullone, or kenpaullone.

### Claim 28 (depends on 27)

The method of claim 27, wherein the paullone is azakenpaullone.

### Claim 29 (depends on 17)

The method of claim 17, wherein the composition is in a pharmaceutically acceptable formulation.

### Claim 30 (depends on 1)

A method of preparing cells or tissue for transplantation to a subject or patient, the method comprising contacting the cell or tissue with the composition of claim 1, wherein the composition is effective to stimulate or increase neurogenesis in the cell or tissue.

### Claim 31 (depends on 30)

The method of claim 30, wherein the one or more biguanides is metformin, phenformin, buformin, or proguanil; and wherein the one or more GSK3-β agents is a paullone.

### Claim 32 (depends on 31)

The method of claim 31, wherein the one or more biguanides is metformin; and
wherein the paullone is alsterpaullone, azakenpaullone, gwennpaullone, or kenpaullone.

### Claim 33 (depends on 32)

The method of claim 32, wherein the paullone is azakenpaullone.

### Claim 34 (depends on 30)

The method of claim 30, wherein the composition is in a pharmaceutically acceptable formulation.
